List of Excipients in Branded Drug BILTRICIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	BILTRICIDE	praziquantel	50419-747	CELLULOSE, MICROCRYSTALLINE
Bayer HealthCare Pharmaceuticals Inc	BILTRICIDE	praziquantel	50419-747	CROSPOVIDONE
Bayer HealthCare Pharmaceuticals Inc	BILTRICIDE	praziquantel	50419-747	HYPROMELLOSE

Biltricide Excipient Strategy and Commercial Opportunities for Praziquantel

Last updated: August 2, 2026

Biltricide is Bayer’s U.S. branded praziquantel product for schistosomiasis and liver fluke infections. Its commercial opportunity is driven by formulation performance, pediatric usability, global access, and supply reliability rather than by a strong modern patent barrier. The current tablet uses a conventional excipient system, leaving room for differentiated oral dosage forms, taste-masked pediatric products, dispersible tablets, and region-specific presentations.

What is Biltricide and which excipients does it contain?

Biltricide contains praziquantel, an anthelmintic drug administered orally for infections caused by schistosomes and liver flukes. The U.S. product is a 600 mg tablet with multiple score marks to support dose division. The FDA labeling identifies the inactive ingredients as corn starch, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate.[1]

Attribute	Biltricide profile
Brand	Biltricide
Active ingredient	Praziquantel
Strength	600 mg
Dosage form	Oral tablet
U.S. sponsor	Bayer HealthCare Pharmaceuticals Inc.
U.S. application	NDA 018714
Primary indications	Schistosomiasis; infections caused by liver flukes
Key excipients	Corn starch, magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate
Administration issue	Tablets are divided into multiple doses based on patient weight
Primary formulation limitation	Strong bitterness and poor pediatric acceptability
Regulatory category	Small-molecule drug, not a biologic

Praziquantel has low water solubility and a pronounced bitter taste. Its pharmacokinetic profile is affected by food, hepatic metabolism, and formulation characteristics. Excipients therefore have potential value in powder wetting, tablet disintegration, dissolution, taste masking, and dose flexibility.

What formulation is protected by Biltricide patents?

Biltricide’s commercial protection is not primarily based on a contemporary formulation patent estate. Praziquantel was discovered and commercialized decades ago, and generic praziquantel products are available in several markets. The principal barriers are regulatory execution, manufacturing quality, clinical positioning, procurement access, and pediatric formulation performance.

The U.S. Orange Book identifies approved products and any listed patents or regulatory exclusivity associated with an application.[2] Biltricide’s competitive exposure is consistent with an established small-molecule product facing generic substitution rather than with a biologic or recently launched specialty drug protected by layered composition-of-matter patents.

Patent categories relevant to praziquantel

Patent category	Strategic relevance for Biltricide
Composition-of-matter patent	Generally not a current commercial barrier for praziquantel
Original process patent	Likely expired or commercially weak in the United States
Tablet formulation patent	Potentially relevant only to a specific excipient, coating, release profile, or manufacturing process
Pediatric taste-masking patent	Potential avenue for new product differentiation
Orally disintegrating tablet patent	Potentially available for a novel formulation design
Liquid or suspension patent	Could protect a specific vehicle, stabilizer system, or dosing device
Method-of-use patent	Possible for new disease populations, regimens, or combination therapy, subject to clinical support
Manufacturing patent	Potentially valuable for higher-purity praziquantel, polymorph control, particle engineering, or continuous processing

A new excipient combination would not automatically create meaningful exclusivity. Patent strength would depend on claim breadth, unexpected technical results, freedom-to-operate analysis, and whether competitors could design around the claimed formulation.

When does Biltricide lose exclusivity?

Biltricide’s core praziquantel exclusivity has already matured. The relevant commercial question is not the date of basic drug-patent expiry but whether a new formulation or use can obtain independent protection.

Exclusivity type	Biltricide assessment
New chemical entity exclusivity	Expired
Core composition patent	Historic protection; not a current primary barrier
Pediatric exclusivity	No current commercial significance identified
Orphan-drug exclusivity	Not the principal U.S. protection mechanism for the marketed product
Formulation exclusivity	Depends on any separately protected approved formulation
Method-of-use exclusivity	Depends on approved labeling and listed patents
Generic substitution risk	High for conventional praziquantel tablets
Biosimilar risk	None; praziquantel is a small molecule

A company commercializing a differentiated praziquantel product would need to build protection around the new dosage form, delivery system, manufacturing process, or approved clinical use. A simple tablet containing the same active ingredient would face limited defensibility.

How important are excipients to praziquantel performance?

Excipients have four main commercial functions in praziquantel products.

Improving dissolution

Praziquantel has limited aqueous solubility. Wetting agents, surfactants, particle-size reduction, solid dispersions, and lipid-based systems can improve dissolution. Sodium lauryl sulfate is present in the Biltricide excipient system and may support wetting and disintegration.

Potential approaches include:

• Surfactant-assisted tablets
• Amorphous solid dispersions
• Co-processed excipients
• Nanocrystalline or micronized praziquantel
• Self-emulsifying drug delivery systems
• Lipid-based capsules or suspensions
• Cyclodextrin or polymer-based solubilization

A dissolution improvement is commercially relevant only if it produces a measurable benefit in bioavailability, dose consistency, administration with food, or reduced dose burden.

Masking bitterness

Taste is one of the largest barriers to pediatric praziquantel use. Children may reject conventional tablets because praziquantel is intensely bitter. A taste-masked product could use:

• Polymer coating of praziquantel particles
• Ion-exchange resin complexes
• Lipid or phospholipid barriers
• Microencapsulation
• Multiparticulate granules
• Flavored oral suspensions
• Rapidly dispersible tablets with coated drug particles

The formulation must prevent premature release in the mouth while allowing rapid release in the stomach or intestine. Excessive coating can delay dissolution and create bioequivalence risk.

Supporting dose division

The 600 mg tablet is divided according to body weight. Score lines improve dose flexibility, but tablet fragments can be difficult for young children to handle accurately. A more scalable approach would use:

• 150 mg or 300 mg tablets
• Dispersible tablets
• Sachets containing dose-calibrated granules
• Oral suspension with an oral syringe
• Multiparticulate capsules
• Weight-band dosing packs

Dose flexibility has high value in mass drug administration programs and pediatric treatment because dosing is commonly calculated by body weight.

Improving manufacturing robustness

The excipient system must support uniformity across high-volume production. Corn starch and microcrystalline cellulose can support tablet compression and disintegration. Povidone can function as a binder, while magnesium stearate acts as a lubricant. Sodium lauryl sulfate can improve wetting but may affect powder flow, tablet strength, dissolution, and gastrointestinal tolerability if used at higher levels.

A reformulation should evaluate:

• Content uniformity
• Tablet tensile strength
• Friability
• Disintegration time
• Dissolution across pH conditions
• Stability under heat and humidity
• Packaging compatibility
• Extractables and leachables
• Palatability
• Dose recovery after splitting or dispersion

What pediatric formulation opportunities exist for Biltricide?

Pediatric formulation is the strongest excipient-led opportunity. The World Health Organization has identified praziquantel as a priority medicine for children and has supported development of child-friendly formulations for schistosomiasis treatment.[3]

Dispersible tablets

A dispersible tablet can be placed in a small volume of water before administration. Its advantages include:

• Lower manufacturing complexity than a liquid
• Better stability than an aqueous suspension
• Reduced shipping weight
• Suitability for decentralized treatment
• More precise dosing than manually split tablets

The principal technical challenge is taste. A dispersible tablet that releases unmasked praziquantel in the mouth may have poor acceptance.

Oral suspension

A ready-to-use suspension offers the most familiar pediatric presentation. The excipient system may include:

• Suspending polymers
• Wetting agents
• Buffers
• Preservatives
• Sweeteners
• Flavors
• Antifoaming agents
• Density modifiers

A dry powder for reconstitution could reduce stability and transport problems. It would require validated reconstitution instructions, a suitable dosing device, and adequate in-use stability.

Mini-tablets and granules

Multiparticulates may provide more accurate weight-based dosing than a large scored tablet. Coated granules can combine taste masking with flexible dosing. They can be packaged in sachets or incorporated into soft food, subject to compatibility and administration studies.

Product concept	Commercial value	Principal development risk
600 mg conventional tablet	Low differentiation	Generic substitution
300 mg scored tablet	Moderate	Limited patent defensibility
150 mg pediatric tablet	Moderate to high	Manufacturing scale and regulatory strategy
Dispersible taste-masked tablet	High	Taste masking versus dissolution
Ready-to-use suspension	High	Stability, preservatives, shipping
Powder for reconstitution	High	Reconstitution control and in-use stability
Coated granules in sachets	High	Dose uniformity and packaging
Orally disintegrating tablet	Moderate to high	Bitterness and mouthfeel

What regulatory pathways apply to a new praziquantel formulation?

A new U.S. product could pursue several regulatory routes depending on the formulation and reference product.

Abbreviated new drug application

An ANDA may be appropriate where the product is therapeutically equivalent to a listed reference product and meets bioequivalence, quality, labeling, and manufacturing requirements. A materially different dosage form, pediatric presentation, or delivery system may complicate the ANDA pathway.

505(b)(2) application

A 505(b)(2) application may be more suitable for a novel dosage form, new formulation, new route, or new clinical use that relies partly on existing findings. This route can support differentiated products while reducing the need to repeat the entire development program.

Potential 505(b)(2) concepts include:

• Pediatric liquid praziquantel
• Taste-masked dispersible tablets
• A new strength supporting weight-band dosing
• A formulation with demonstrated pharmacokinetic advantages
• A product designed for administration through feeding tubes

The regulatory value depends on whether the reformulation creates a meaningful clinical or administration benefit. Excipients that only change manufacturing performance may not support a strong commercial premium.

What generic entry risks exist for Biltricide?

Generic entry risk is high because praziquantel is an established small molecule with mature manufacturing knowledge. Generic competitors can target the same conventional tablet market and compete on price, procurement qualification, and supply reliability.

The main risks to the branded product are:

1. Price erosion in conventional tablets.
2. Hospital and wholesaler substitution.
3. Loss of formulary preference.
4. Tender competition in endemic markets.
5. Parallel procurement of lower-cost international products.
6. Limited willingness to pay for excipient changes without a clinical or operational benefit.

A differentiated pediatric product could reduce direct substitution if it has a separate dosage form, proprietary taste-masking system, superior dosing accuracy, or procurement advantages.

Which companies are challenging Biltricide?

The competitive field includes generic pharmaceutical manufacturers producing praziquantel tablets, international suppliers serving endemic-country programs, and developers of child-friendly praziquantel formulations. Competition is fragmented by geography and regulatory market.

The most relevant competitors are not limited to companies selling a product under the Biltricide label. They include manufacturers with:

• U.S.-approved generic praziquantel products
• WHO-prequalified or procurement-qualified products
• Pediatric dispersible tablets
• Institutional and government supply contracts
• Veterinary praziquantel manufacturing capacity
• Contract manufacturing capability for high-volume anthelmintic products

Veterinary praziquantel products are not substitutes for human Biltricide. Their excipients, quality standards, labeling, and regulatory status differ.

What licensing deals and partnerships could support a praziquantel product?

The most commercially relevant partnerships would involve formulation, pediatric development, manufacturing, and public-sector procurement.

Partnership type	Strategic purpose
University or nonprofit license	Access to taste-masking or pediatric formulation technology
Contract development and manufacturing organization	Scale-up of dispersible tablets, granules, or suspension
Public-health organization	Clinical development and endemic-market access
Regional pharmaceutical partner	Registration and distribution in schistosomiasis-endemic countries
Packaging supplier	Unit-dose sachets, oral syringes, or moisture-protective packaging
Drug-delivery company	Lipid, polymer, resin, or nanoparticle formulation
Procurement agency	Volume commitments and tender access

A licensing strategy should prioritize rights to the delivery technology, not merely rights to praziquantel. The active ingredient is widely available and offers limited standalone exclusivity.

How strong is the Biltricide patent estate?

The patent estate is weak for conventional praziquantel tablets and potentially stronger for a genuinely differentiated formulation.

Patent feature	Estimated strategic strength
Praziquantel molecule	Low current value because of age and generic availability
Conventional tablet excipients	Low unless claims cover a narrow but necessary combination
Taste-masked pediatric formulation	Moderate to high if supported by performance data
Novel dispersion or solubilization system	Moderate
New manufacturing process	Moderate if it delivers reproducible quality or cost advantages
New clinical use	Variable and dependent on clinical evidence
Device and packaging claims	Moderate for dosing accuracy and reconstitution systems
Broad excipient claims	Often vulnerable to enablement and obviousness challenges

The most defensible claims would combine a specific praziquantel particle or coating architecture with measurable dissolution, palatability, stability, or pharmacokinetic results. Generic claims covering common excipients such as cellulose, starch, povidone, or magnesium stearate would likely have limited blocking power.

What commercial opportunities exist beyond Biltricide tablets?

The strongest opportunities are concentrated in pediatric treatment and public-health delivery.

Pediatric endemic-market product

A low-cost dispersible or granulated product could target children with schistosomiasis in Africa, Latin America, and other endemic regions. Success would depend on WHO-aligned dosing, public-sector procurement, local registration, and supply economics.

Premium pediatric formulation

A branded product could command a premium if it offers better taste, lower dosing errors, and easier administration. The addressable market is narrower than the conventional tablet market but may be less exposed to direct generic substitution.

Hospital and feeding-tube formulation

A liquid or dispersible dosage form designed for patients unable to swallow tablets could address hospital, pediatric, and institutional settings. Claims around uniform dispersion, tube compatibility, and dose recovery could support product differentiation.

Fixed-dose combinations

A praziquantel combination with another antiparasitic could simplify treatment in selected disease settings. This would require clinical justification, compatibility data, and a regulatory strategy addressing each active ingredient.

Manufacturing and supply-chain platform

A high-quality, low-cost praziquantel manufacturing process could create value through contract supply, government tenders, and regional licensing. Process economics may matter more than patent exclusivity in this market.

What is the outlook for Biltricide revenue exposure?

Biltricide revenue is exposed to generic price competition in conventional tablets, but demand for praziquantel remains supported by disease burden and public-health programs. The key commercial variables are:

• Treatment volumes in endemic countries
• Government and nonprofit procurement
• Pediatric treatment expansion
• Generic pricing
• Manufacturing capacity
• Product availability during mass drug administration campaigns
• Regulatory approval of child-friendly formulations
• Hospital demand for patients unable to swallow tablets

A formulation company should not rely on brand loyalty. It should build a product around dosing accuracy, palatability, stability, procurement efficiency, or administration in underserved populations.

Key Takeaways

• Biltricide contains 600 mg praziquantel and a conventional excipient system of corn starch, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate.[1]
• The core praziquantel molecule has limited current patent value, and generic substitution is the main commercial threat.
• Pediatric taste masking is the clearest excipient-driven opportunity.
• Dispersible tablets, coated granules, mini-tablets, and stable oral suspensions have stronger commercial differentiation than another conventional tablet.
• A 505(b)(2) strategy may be relevant for a materially differentiated formulation.
• The strongest patent claims would link specific excipient or particle technologies to measurable performance benefits.
• Public-health procurement, pediatric usability, and reliable manufacturing are likely to determine commercial success more than brand positioning.
• Biosimilar risk is not relevant because praziquantel is a small molecule.

FAQs About Biltricide Excipients and Commercial Strategy

Can Biltricide be reformulated as a liquid?

Yes. A liquid or dry powder for reconstitution could improve pediatric administration, but the formulation would require validated taste masking, suspension uniformity, chemical stability, preservative performance, and an accurate dosing device.

Is praziquantel suitable for an orally disintegrating tablet?

Yes, but bitterness is the central technical constraint. A successful orally disintegrating tablet would need rapid disintegration without releasing unacceptable levels of praziquantel in the mouth.

Can excipients create new patent protection for praziquantel?

Yes, if the formulation contains a novel and non-obvious excipient or delivery system supported by technical results. The strongest protection would generally cover a defined formulation architecture and its performance, not the use of common excipients alone.

Does Biltricide have biosimilar competition?

No. Biosimilars apply to biologic products. Praziquantel is a chemically synthesized small-molecule drug and faces generic, not biosimilar, competition.

What is the highest-value formulation opportunity for praziquantel?

A taste-masked, weight-band pediatric product with flexible dosing and strong stability is the highest-value opportunity. It addresses the principal administration barrier while supporting public-health procurement and differentiated regulatory positioning.

References

1. U.S. Food and Drug Administration. (2023). Biltricide (praziquantel) tablets, 600 mg: Prescribing information. Bayer HealthCare Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. World Health Organization. (2022). WHO guideline on control and elimination of human schistosomiasis. World Health Organization. https://www.who.int/publications/i/item/9789240041608